A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer (MAGNITUDE)
Castration-Resistant Prostatic Cancer
About this trial
This is an interventional treatment trial for Castration-Resistant Prostatic Cancer
Eligibility Criteria
Inclusion Criteria:
HRR gene alteration (as identified by the sponsor's required assays) as follows:
- Cohort 1: positive for HRR gene alteration
- Cohort 2: not positive for DRD (that is, HRR gene alteration)
- Cohort 3: eligible by HRR status
- Metastatic disease documented by positive bone scan or metastatic lesions on computed tomography (CT) or magnetic resonance imaging (MRI)
- Metastatic prostate cancer in the setting of castrate levels of testosterone less than or equal to (<=) 50 nanogram per deciliter (ng/dL) on a gonadotropin releasing hormone analog (GnRHa) or bilateral orchiectomy
- Able to continue GnRHa during the study if not surgically castrate
- Score of <= 3 on the brief pain inventory-short form (BPI-SF) question number 3 (worst pain in last 24 hours)
Exclusion Criteria:
- Prior treatment with a poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor
- Systemic therapy (that is, novel second-generation AR-targeted therapy such as enzalutamide, apalutamide, or darolutamide; taxane-based chemotherapy, or more than 4 months of abiraterone acetate plus prednisone [AAP] prior to randomization) in the metastatic castration-resistant prostate cancer (mCRPC) setting; or AAP outside of the mCRPC setting
- Symptomatic brain metastases
- History or current diagnosis of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML)
- Other prior malignancy (exceptions: adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer, or any other cancer in situ currently in complete remission) <= 2 years prior to randomization, or malignancy that currently requires active systemic therapy
Sites / Locations
- Urology Centers Of Alabama
- Mayo Clinic Arizona
- Urological Associates of Southern Arizona, P.C.
- Arkansas Urology
- Kaiser Permanente
- San Bernardino Urological Associates
- University of California San Francisco
- Sansum Clinic Pharm
- The Urology Center of Colorado
- Colorado Clinical Research
- VA Connecticut Healthcare
- Bay Pines VA Healthcare System
- Advanced Urology Institute
- University of Florida Health Jacksonville
- Mayo Clinic - Division Of Hematology/oncology
- Veterans Affairs Medical Ctr
- Fort Wayne Medical Oncology and Hematology
- First Urology
- University of Kansas Medical Center
- Norton Healthcare
- Ochsner Clinic Foundation
- Rcca Md, Llc
- Chesapeake Urology Research Associates
- Massachusetts General
- Michigan Institute of Urology
- Kansas City Veterans Affairs Medical Center
- Adult Pediatric Urology & Urogynecology, P.C
- Nebraska Cancer Specialists
- Comprehensive Cancer Centers of Nevada
- Delaware Valley Urology, LLC
- New York Oncology Hematology
- Icahn School of Medicine at Mount Sinai - The Derald H. Ruttenberg
- Memorial Sloan Kettering Cancer Center
- Upstate Cancer Center
- Helios Clinical Research, LLC
- Oregon Urology Institute
- MidLantic Urology
- Lancaster Urology
- VA Pittsburgh
- Carolina Urologic Research Center
- Urology Associates
- Houston Metro Urology
- University of Texas MD Anderson Cancer Center
- Utah Cancer Specialists
- Salem VA Medical Center
- Urology of Virginia, PLCC
- NorthWest Medical Specialties, PLLC
- Hospital Aleman
- Centro Oncológico Korben
- Centro de Urologia (CDU)
- CEMIC Saavedra
- Cemaic - Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica
- Hospital Privado - Centro Medico de Cordoba
- Instituto de Investigaciones Clinicas Mar del Plata
- Hospital Privado de Comunidad
- Centro de Investigacion Pergamino SA
- Sanatorio Britanico de Rosario
- Sanatorio Parque
- ARS Médica
- Royal Adelaide Hospital
- Pindara Private Hospital
- Sunshine Coast University Hospital
- Princess Alexandra Hospital
- St. Vincent's Hospital Sydney
- Royal Hobart Hospital
- Macquarie University
- Eye Surgery Associates
- Peter MacCallum Cancer Centre
- Fiona Stanley Hospital
- Hollywood Private Hospital
- Prince Of Wales Hospital
- Sydney Adventist Hospital
- Wollongong Private Hospital
- OLV Ziekenhuis Aalst
- ZNA Middelheim
- Grand Hopital de Charleroi, site Notre Dame
- AZ Maria Middelares
- Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman
- ZNA Jan Palfijn
- Fundacao Pio XII
- PERSONAL - Oncologia de Precisão e Personalizada
- Sociedade Beneficente de Senhoras - Hospital Sirio Libanes HSL Unidade Brasilia
- CIONC - Centro Integrado de Oncologia de Curitiba
- Pronutrir
- Associacao de Combate ao Cancer em Goias - Hospital de Cancer Araujo Jorge
- Oncosite - Centro de Pesquisa Clínica em Oncologia Ltda
- Fundação São Francisco Xavier
- Instituto Joinvilense de Hematologia e Oncologia Ltda-Centro de Hematologia e Oncologia
- Medradius Clinica de Medicina Nuclear e Radiologia de Maceio Ltda.
- Liga Norte Riograndense Contra O Cancer
- Irmandade Santa Casa de Misericordia de Porto Alegre
- Hospital Ernesto Dornelles
- Ministerio da Saude - Instituto Nacional do Cancer
- Universidade do Estado do Rio de Janeiro - UERJ
- Oncoclínicas Rio de Janeiro S.A.
- Instituto de Educacao, Pesquisa e Gestao em Saude Instituto Americas (COI)
- Hospital Santa Isabel
- Fundacao do ABC - Centro Universitario FMABC
- Irmandade Santa Casa de Misericordia de Sao Paulo
- Instituto de Ensino e Pesquisa São Lucas
- Fundacao Faculdade de Medicina - Instituto do Cancer do Estado de Sao Paulo
- Hospital Alemao Oswaldo Cruz
- Fundacao Antonio Prudente - A.C. Camargo Cancer Center
- Instituto de Assistencia Medica ao Servidor Publico Estadual - IAMSPE
- IOS - Instituto de Oncologia de Sorocaba Dr. Gilson Delgado
- Núcleo de Pesquisa São Camilo
- Instituto D'Or de Pesquisa e Ensino (IDOR)
- Instituto do Cancer De Tres Lagoas
- MHAT Deva Maria
- UMHAT 'Dr. Georgi Stranski', EAD
- Complex Oncology Center - Plovdiv EOOD
- Specialized Hospital for Active Treatment in Oncology EAD
- SHATOD 'Dr. Marko Antonov Markov'
- Comprehensive Cancer Center
- Southern Alberta Institute of Urology / Prostate Cancer Centre
- British Columbia Cancer Agency (BCCA) - Vancouver Centre
- British Columbia Cancer Agency - Vancouver Island Centre
- McMaster Institute of Urology
- Cancer Centre of Southeastern Ontario (Kingston Regional Cancer Centre)
- Sunnybrook Health Sciences Center
- University Health Network (UHN) Princess Margaret Cancer Centre
- Centre de Recherche du CHUM
- Saskatoon Cancer Centre
- Cancer Hospital Chinese Academy of Medical Sciences
- Peking University First Hospital
- Beijing Friendship Hospital
- Beijing Cancer Hospital of Peking University
- Peking University Third Hospital
- Beijing Hospital
- Sichuan Provincial People's Hospital
- Southwest Hospital, The Third Military Medical University
- Chongqing University Cancer Hospital
- Fujian Medical University Union Hospital
- Sun Yat-Sen Memorial Hospital Sun Yat-sen University
- Guangzhou First Municipal People's Hospital
- Nanjing Drum Tower Hospital
- Jiangsu Cancer Hospital
- Drug clinical trial ethics committee of Ningbo First Hospital
- Renji Hospital, Shanghai Jiaotong University School of Medicine
- Fudan University Shanghai Cancer Center
- Huashan Hospital Fudan University
- ShangHai Huadong Hospital
- The Fifth People's Hospital of Shanghai, Fudan University
- The First Affiliated Hospital of Soochow University
- Tianjin Medical University Cancer Hospital
- The Central Hospital of Wuhan
- Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology
- Wuxi People's Hospital
- The First Affiliated Hospital of Xi'an Jiaotong University
- Fakultni nemocnice Hradec Kralove
- Krajská nemocnice Liberec
- Uromedical Center s.r.o.
- Multiscan s.r.o.
- Fakultni nemocnice Plzen, Urologicka klinika
- Urologicka klinika 1.LF UK a VFN
- Thomayerova nemocnice, Onkologicka klinika
- Uherskohradistska nemocnice a.s.
- CHRU De Besancon
- Institut Bergonié
- Centre Jean Perrin
- Centre Leon Bérard
- Institut Regional du Cancer de Montpellier Val d'Aurelle
- Polyclinique de Gentilly
- Centre Antoine Lacassagne
- Hopital Europeen Georges-Pompidou
- Institut de Cancérologie de l'Ouest (ICO)
- HIA Begin
- Hôpitaux Universitaires de Strasbourg - Hôpital de Hautepierre
- Städtisches Klinikum Braunschweig gGmbH - Standort Salzdahlumer
- Urologicum Duisburg
- Universitätsklinikum des Saarlandes
- Universitätsklinikum Otto-von-Guericke-Universität Magdeburg
- Universitaetsklinikum Muenster
- Studienpraxis Urologie Drs. Feyerabend
- Semmelweis Egyetem, Urológia Klinika
- Országos Onkológiai Intézet, C Belgyógyászati-Onkológiai és Klinikai Farmakológiai Osztály
- Debreceni Egyetem Klinikai Kozpont
- Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaz
- Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz
- Uro-Clin Kft.
- Szegedi Tudomanyegyetem
- Szegedi Tudomanyegyetem
- Markusovszky Egyetemi Oktatokorhaz
- Asaf Harofe Medical Center
- Rambam Health Care Campus
- Rabin Medical Center
- Sheba Medical Center Tel Hashomer
- AUSL Romagna - Ospedale di Faenza
- Ospedale San Raffaele
- ASST Grande Ospedale Metropolitano Niguarda
- Oncologia Medica A - Ist Naz Tumori G Pascale
- Istituto Oncologico Veneto Iov Irccs Padova
- Oncologia Medica - Azienda Ospedaliero Universitaria Di Parma
- Ospedale S. Maria Della Misericordia Centro Operativo Studi Clinici SC Oncologia Medica
- Azienda Ospedaliero Universitaria Pisana
- Fondazione Policlinico Universitario A. Gemelli IRCCS
- Campus Bio-Medico di Roma
- Azienda Ospedaliera S. Maria Terni
- A.O.U. Città della Salute e della Scienza
- Ospedale Santa Chiara Trento
- Pusan National University Hospital
- Kyungpook National University Chilgok Hospital
- Keimyung University Dongsan Hospital
- Chungnam National University Hospital
- Chonnam National University Hospital
- National Cancer Center
- Seoul National University Bundang Hospital
- Ajou University Hospital
- Seoul National University Hospital
- Severance Hospital, Yonsei University Health System
- Asan Medical Center
- Gangnam Severance Hospital, Yonsei University Health System
- Samsung Medical Center
- The Catholic University of Korea Seoul St. Mary's Hospital
- Hospital Pulau Pinang
- Hospital Sultan Ismail
- Hospital Likas
- Hospital Kuala Lumpur
- University Malaya Medical Centre
- Sarawak General Hospital
- iBiomed Research Unit
- Mexico Centre for Clinical Research, S.A. de C.V.
- Consultorio de Especialidad en Urologia Privado
- Avix Investigacion Clinica, S.C.
- Consultorio Privado
- NKI-AVL, Amsterdam
- Universitair Medisch Centrum Groningen
- MC Haaglanden Lok Antoniushove - Afd.Interne - INT
- St. Antonius Ziekenhuis (St. Antonius Hospital)
- Canisius-Wilhelminaziekenhuis
- Erasmus MC
- Zuyderland Medical Center
- Szpital Uniwersytecki NR 1 IM. Dr. Antoniego Jurasza
- Centrum Onkologii im. Prof. F. Lukaszczyka
- Uniwersyteckie Centrum Kliniczne
- Szpitale Pomorskie Sp. z o.o.
- Wojewodzki Szpital Specjalistyczny im. M. Kopernika w Lodzi
- Urologica Praktyka Lekarska Adam Marcheluk
- Pomorski Uniwersytet Medyczny w Szczecinie
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy
- Dolnoslaskie Centrum Onkologii
- Hospitais da universidade de Coimbra
- Instituto Portugues de Oncologia de Coimbra Francisco Gentil, EPE
- Centro Hospitalar Lisboa Norte, EPE/Hosp. Santa Maria
- Champalimaud Foundation Champalimaud Centre
- H. Santo António - Centro Hospitalar do Porto
- VA Caribbean Healthcare System
- Altai Regional Oncology Dispensary
- Ivanovo Regional Oncology Dispensary
- GUZ Kursk Regional Oncology Dispensary
- Russian Scientific Center of Roentgenoradiology
- Moscow City Clinical Hospital # 62
- Clinical Diagnostic Centre of Nizhny Novgorod Region
- Clinical Oncology Dispensary
- LLC Novaya Clinica
- Pyatigorsk Interdistrict Oncology Dispensary
- Private Medical Institution Euromedservice
- Leningrad Regional Oncology Dispensary
- Russian Scientific Center of Radiology and Surgical Technologies
- Republican Oncology Dispensary
- Oncologic Dispensary No.2
- Tambov Regional Oncology Clinical Dispansary
- Tomsk Cancer Research Institute
- Medical-sanitary unit 'Neftyanik'
- Vologda Regional Oncological Dispensary
- Clinresco Centres Pty Ltd
- Clinical Research Unit
- Hosp. Del Mar
- Hosp. de La Santa Creu I Sant Pau
- Hosp. Clinic I Provincial de Barcelona
- Hospital Juan Canalejo
- Hosp. de Jerez de La Frontera
- Hosp. Univ. Ramon Y Cajal
- Hosp. Clinico San Carlos
- Hosp. Virgen de La Victoria
- Hosp. Quiron Madrid Pozuelo
- Corporacio Sanitari Parc Tauli
- Hosp. Univ. Marques de Valdecilla
- Hosp. Univ. I Politecni La Fe
- Södersjukhuset
- Karolinska Universitetssjukhuset Solna
- Akademiska Sjukhuset
- Kaohsiung Medical University Chung-Ho Memorial Hospital
- China Medical University Hospital
- Taichung Veterans General Hospital
- Tungs' Taichung MetroHarbor Hospital
- Chi Mei Medical Center - Yong Kang
- National Taiwan University Hospital
- Taipei Veterans General Hospital
- Chang Gung Memorial Hospital
- Cukurova University, Faculty of Medicine
- Dr.Abdurrahman Yurtaslan Oncology Training and Research Hospital
- Ankara Bilkent Sehir Hastanesi
- Akdeniz University Medical Faculty
- Trakya University Medical Faculty
- Istanbul University Cerrahpasa Medical Faculty
- Bakirkoy Training and Research Hospital
- Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi
- IEU Medical Point Hospital
- Kocaeli University Medical Faculty
- Communal Nonprofit Enterprise 'Cherkasy Regional Oncology Dispensary Of Cherkasy Regional Council'
- Ce 'Dnipropetrovsk Regional Clinical Hospital N.A. Mechnikov' of Dnipropetrovsk Rc
- Municipal Institution 'Clinical Oncology Dispensary' Under Dnipropetrovsk Regional Council
- Dnipropetrovsk State Medical Academy, Dnipropetrovsk City Multifield Clinical Hospital # 4
- Ivano-Frankivsk Regional Clinical Hospital
- Municipal non-profit enterprise 'Regional Center of Oncology'
- Regional Clinical Center of Urology and Nephrology n.a. V.I. Shapoval
- State Institution National Cancer Institute
- State Institution Institute of Urology NAMS of Ukraine based on Kyiv City Clinical Oncology Center
- Communal Noncommercial Enterprise of Lviv Regional Council 'Lviv Regional Clinical Hospital'
- ME 'Poltava Regional Clinical Hospital n.a. M.V. Sklifosovsky of the Poltava Regional Council'
- Municipal Oncology Centre of Uzhgorod Central Municipal Clinical Hospitlal
- Royal Blackburn Hospital
- Royal Lancaster Infirmary
- UCL Cancer Institute
- Torbay Hospital-Devon
- Royal Cornwall Hospitals NHS Trust - Royal Cornwall Hospital
- New Cross Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
Cohort 1: Participants with mCRPC and HRR Gene Alteration
Cohort 2: Participants with mCRPC and No HRR Gene Alteration
Cohort 3 (Open-label): Participants with mCRPC
Participants with L1 metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alteration will receive combination of niraparib 200 milligrams (mg) or matching placebo and abiraterone acetate (AA) 1000 mg plus prednisone 10 mg. In the open label extension (OLE) phase participants earlier receiving the combination of niraparib and AAP may continue to receive open-label combination of niraparib 200 mg and AA 1000 mg plus prednisone 10 mg and those receiving placebo and AAP may cross over depending on the outcome of study to receive open-label combination of niraparib 200 mg and AA 1000 mg plus prednisone 10 mg.
Participants with L1 mCRPC and no HRR Gene alteration will receive combination of niraparib 200 mg or matching placebo and AA 1000 mg plus prednisone 10 mg. In the OLE phase participants earlier receiving the combination of niraparib and AAP may continue to receive open-label combination of niraparib 200 mg and AA 1000 mg plus prednisone 10 mg and those receiving placebo and AAP may cross over depending on the outcome of study to receive open-label combination of niraparib 200 mg and AA 1000 mg plus prednisone 10 mg.
Participants with mCRPC will receive a new formulation of niraparib 200 mg and AA 1000 mg tablets plus prednisone 10 mg.